Ahmad, J. Et Al. 2018. Tenofovir is more potent over entecavir in reducing the viral load in patients of hepatitis B reactivation presenting as Acute on Chronic Liver Failure (ACLF)-Results of multination study from APASL-ACLF Research Consortium (AARC). International Liver Congress (ILC) , (Paris, France).

Ahmad, J., Choudhury, A., Kumar, M., Al-Mahtab, M., Rahman, S., Ning, Q., ... Ma, K.(2018). Tenofovir is more potent over entecavir in reducing the viral load in patients of hepatitis B reactivation presenting as Acute on Chronic Liver Failure (ACLF)-Results of multination study from APASL-ACLF Research Consortium (AARC) . International Liver Congress (ILC), Paris, France

Ahmad, J. Et Al. "Tenofovir is more potent over entecavir in reducing the viral load in patients of hepatitis B reactivation presenting as Acute on Chronic Liver Failure (ACLF)-Results of multination study from APASL-ACLF Research Consortium (AARC)," International Liver Congress (ILC), Paris, France, 2018

Ahmad, J. Et Al. "Tenofovir is more potent over entecavir in reducing the viral load in patients of hepatitis B reactivation presenting as Acute on Chronic Liver Failure (ACLF)-Results of multination study from APASL-ACLF Research Consortium (AARC)." International Liver Congress (ILC) , Paris, France, 2018

Ahmad, J. Et Al. (2018) . "Tenofovir is more potent over entecavir in reducing the viral load in patients of hepatitis B reactivation presenting as Acute on Chronic Liver Failure (ACLF)-Results of multination study from APASL-ACLF Research Consortium (AARC)." International Liver Congress (ILC) , Paris, France.

@conferencepaper{conferencepaper, author={J. Ahmad Et Al. }, title={Tenofovir is more potent over entecavir in reducing the viral load in patients of hepatitis B reactivation presenting as Acute on Chronic Liver Failure (ACLF)-Results of multination study from APASL-ACLF Research Consortium (AARC)}, congress name={International Liver Congress (ILC)}, city={Paris}, country={France}, year={2018}}